Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer. O'Rourke K. Cancer 2022;128:938.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

O'Rourke K. Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer. Cancer 2022;128:938.
PMID: 35147987